A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

NCT03657043 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions

DRUG: tisotumab vedotin

Sponsor

Seagen Inc.

Collaborators

[object Object]